Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference

  Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual
                            Healthcare Conference

PR Newswire

SAN DIEGO, Nov. 6, 2012

SAN DIEGO, Nov. 6, 2012 /PRNewswire/ --Halozyme Therapeutics, Inc. (NASDAQ:
HALO) will be presenting at the Lazard Capital Markets 9^th Annual Healthcare
Conference in New York on Tuesday, November 13, 2012 at 1:30 p.m. PT/4:30 p.m.
ET. Kurt Gustafson, Chief Financial Officer, Halozyme Therapeutics, will
provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's
corporate website at www.halozyme.com, and a recording will be made available
for 90 days following the event. To access the live webcast, please log on to
Halozyme's website approximately fifteen minutes prior to the presentation to
register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing
and commercializing innovative products that advance patient care. With a
diversified portfolio of enzymes that target the extracellular matrix, the
Company's research focuses primarily on a family of human enzymes, known as
hyaluronidases, that increase the absorption and dispersion of biologics.
Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology
and dermatology that have significant unmet medical need. The Company markets
HYLENEX^® recombinant (hyaluronidase human injection) and has partnerships
with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San
Diego, CA. For more information on how we are innovating, please visit our
corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com

SOURCE Halozyme Therapeutics, Inc.

Website: http://www.halozyme.com